ERBB2 and breast carcinoma: New clinical trials for HER2+ breast cancer populations may also add additional indications for T-DXd as studies are ongoing in the neoadjuvant setting (DESTINY-Breast11) [20], adjuvant setting for patients with residual disease compared to T-DM1 (DESTINY-Breast05) [21], and as a first-line therapy for metastatic disease comparing T-DXd versus pertuzumab, trastuzumab and taxane chemotherapy (DESTINY-Breast09) [22].